Literature DB >> 26834009

Predictors for papillary thyroid cancer persistence and recurrence: a retrospective analysis with a 10-year follow-up cohort study.

Taciana Padilha de Castro1,2, William Waissmann2, Taynãna César Simões3, Rossana Corbo R de Mello1,4, Denise P Carvalho1,5.   

Abstract

OBJECTIVE: We aimed to determine outcome predictors of papillary thyroid cancer (PTC) persistence and recurrence, separately. CONTEXT: The factors contributing to either persistence or recurrence of PTC are poorly defined, as both outcomes are usually evaluated together. DESIGN AND PATIENTS: In this 10-year follow-up cohort study, 190 PTC patients were evaluated (18-85 years old; registered from 1 January 1990 to31 December 1999 at a Brazilian Cancer Care referral Hospital). After initial surgery, we examined persistence (disease detected up to 1 year), recurrence (disease detected after 1 year) and PTC-free status (disease absence during follow-up). MEASUREMENTS: Outcome predictors were modelled using multinomial logit regression analysis.
RESULTS: The univariate analysis showed that persistence and recurrence were significantly associated with lymph node metastasis (OR = 12·33; OR = 2·84, respectively), local aggressiveness (OR = 5·22; OR = 3·35) and extrathyroidal extension (OR = 5·07; OR = 7·11). Persistence was associated with male sex (OR = 3·49), age above 45 years old at diagnosis (OR = 1·03), macroscopic lymph node metastasis (OR = 5·85), local aggressiveness (OR = 5·22), each 1-cm tumour size increase (OR = 1·34), a cancer care referral hospital as the place of initial surgery (OR = 2·3), thyroidectomy or near total thyroidectomy(OR = 3·03) and neck dissection (OR = 3·19). Recurrence was associated with the time of radioactive iodine ((131) I) therapy (OR = 3·71). After data modelling, persistence was associated with macroscopic lymph node metastasis (OR = 6·17), 1-cm increases in tumour size (OR = 1·30) and thyroidectomy or near total thyroidectomy (OR = 3·82), while recurrence was associated with surgery at referral hospital (OR = 3·79).
CONCLUSIONS: The best predictors of persistence were tumour size and macroscopic lymph node metastasis; when the initial surgery is of quality, the recurrence depends more on tumour's biology aspects.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26834009     DOI: 10.1111/cen.13032

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Performance of ATA Risk Stratification Systems, Response to Therapy, and Outcome in an Indian Cohort of Differentiated Thyroid Carcinoma Patients: A Retrospective Study.

Authors:  Rony Ruben; Praveen V Pavithran; V Usha Menon; Vasantha Nair; Harish Kumar
Journal:  Eur Thyroid J       Date:  2019-06-26

2.  Predictive value of LN metastasis detected by 18F-FDG PET/CT in patients with papillary thyroid cancer receiving iodine-131 radiotherapy.

Authors:  Chao Li; Jian Zhang; Hui Wang
Journal:  Oncol Lett       Date:  2019-06-19       Impact factor: 2.967

3.  The age threshold of the 8th edition AJCC classification is useful for indicating patients with aggressive papillary thyroid cancer in clinical practice.

Authors:  Krzysztof Kaliszewski; Dorota Diakowska; Łukasz Nowak; Beata Wojtczak; Jerzy Rudnicki
Journal:  BMC Cancer       Date:  2020-11-30       Impact factor: 4.430

Review 4.  Papillary Thyroid Cancer Prognosis: An Evolving Field.

Authors:  Salvatore Ulisse; Enke Baldini; Augusto Lauro; Daniele Pironi; Domenico Tripodi; Eleonora Lori; Iulia Catalina Ferent; Maria Ida Amabile; Antonio Catania; Filippo Maria Di Matteo; Flavio Forte; Alberto Santoro; Piergaspare Palumbo; Vito D'Andrea; Salvatore Sorrenti
Journal:  Cancers (Basel)       Date:  2021-11-07       Impact factor: 6.639

5.  Clinical features of recently diagnosed papillary thyroid carcinoma in elderly patients aged 65 and older based on 10 years of sonographic experience at a single institution in Korea.

Authors:  Eun Sil Kim; Younghen Lee; Hyungsuk Seo; Gil Soo Son; Soon Young Kwon; Young-Sik Kim; Ji-A Seo; Nan Hee Kim; Sang-Il Suh; Inseon Ryoo; Sung-Hye You
Journal:  Ultrasonography       Date:  2017-04-13

6.  NKX2.5 is expressed in papillary thyroid carcinomas and regulates differentiation in thyroid cells.

Authors:  Ricardo Cortez Cardoso Penha; Luisa Aguirre Buexm; Fabiana Resende Rodrigues; Taciana Padilha de Castro; Maria Carolina S Santos; Rodrigo Soares Fortunato; Denise P Carvalho; Luciene C Cardoso-Weide; Andrea C F Ferreira
Journal:  BMC Cancer       Date:  2018-05-02       Impact factor: 4.430

7.  Expression of activator protein-1 in papillary thyroid carcinoma and its clinical significance.

Authors:  Cheng Xiao; Yonglian Huang; Qiyuan Gao; Zijian Feng; Qi Li; Zhen Liu
Journal:  World J Surg Oncol       Date:  2019-01-31       Impact factor: 2.754

8.  Microscopic Positive Tumor Margin Increases Risk for Disease Persistence but Not Recurrence in Patients with Stage T1-T2 Differentiated Thyroid Cancer.

Authors:  Olfat Kamel Hasan; Sarah De Brabandere; Irina Rachinsky; David Laidley; Danielle MacNeil; Stan Van Uum
Journal:  J Thyroid Res       Date:  2020-01-10

9.  Molecular Predictors for Advanced Papillary Thyroid Carcinoma Recurrence.

Authors:  Taciana Padilha de Castro; Ricardo Cortez Cardoso Penha; Luisa Aguirre Buexm; Flávia Nascimento de Carvalho; Raquel de Vasconcellos Carvalhaes Oliveira; Fernando Vaz Agarez; Luciana Wernersbach Pinto; Denise P Carvalho
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-05       Impact factor: 5.555

10.  Predictors of persistent disease following initial thyroid cancer management.

Authors:  Shaza A Samargandy; Mazin A Merdad
Journal:  Saudi Med J       Date:  2020-08       Impact factor: 1.484

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.